{"entity":{"id":"hla-a02-restriction","kind":"term","name":"HLA-A*02:01 restriction","aka":[],"tldr":"Some T-cell-receptor drugs only work in people with a particular immune 'tissue type'. About half of people of European ancestry have it; far fewer in some other populations.","summary":"Tebentafusp, brenetafusp, and afamitresgene autoleucel recognise peptides presented on HLA-A*02:01, so eligibility requires a blood test. Frequencies vary from ~45-50% in Europeans to under 20% in some African and East Asian populations, creating an equity problem that next-generation TCR agents against other alleles aim to address.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/HLA-A*02","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/HLA-A*02"}],"tags":[],"related":[],"cancers":["melanoma","sarcoma"],"sections":[],"technologies":["tcr-t","t-cell-engager"],"targets":[],"drugs":["tebentafusp","brenetafusp","afamitresgene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Immunology"},"route":"/terms/hla-a02-restriction/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"drug":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"},{"id":"brenetafusp","kind":"drug","name":"Brenetafusp","route":"/drugs/brenetafusp/"},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/"}],"idea":[{"id":"idea-bio2-antigen-presentation-triage","kind":"idea","name":"Check whether a tumour can still show itself to the immune system","route":"/ideas/idea-bio2-antigen-presentation-triage/"},{"id":"idea-prame-tcr-beyond-a02","kind":"idea","name":"TCR therapeutics for non-HLA-A*02 patients","route":"/ideas/idea-prame-tcr-beyond-a02/"}],"target":[{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/"}],"pathway":[{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/"}],"term":[{"id":"ss18-ssx-fusion","kind":"term","name":"SS18::SSX fusion (synovial sarcoma)","route":"/terms/ss18-ssx-fusion/"},{"id":"uveal-melanoma-prognostic-markers","kind":"term","name":"Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)","route":"/terms/uveal-melanoma-prognostic-markers/"}],"biomarker":[{"id":"hla-a-02-01","kind":"biomarker","name":"HLA-A*02:01 (HLA typing for TCR therapies)","route":"/biomarkers/hla-a-02-01/"}]}}